Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Inserm · Université Paris Cité · +63 more institutions
Abstract
The genetics underlying severe COVID-19 The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang et al. used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and…
Citation impact
- FWCI
- 57.94
- Percentile
- 100%
- References
- 48
Authors
752- PBPaul BastardCorresponding
Inserm, Université Paris Cité, Institut des Maladies Génétiques Imagine, Rockefeller University
- LBLindsey B. RosenCorresponding
National Institutes of Health, National Institute of Allergy and Infectious Diseases
- QZQian ZhangCorresponding
Rockefeller University
- EMEleftherios MichailidisCorresponding
Rockefeller University
- HHHans-Heinrich HoffmannCorresponding
Rockefeller University
Topics & keywords
- Autoantibody
- Immunology
- Asymptomatic
- Medicine
- Pneumonia
- Antibody
- Phenocopy
- Coronavirus
- Good health and well-being
Funding
- UDU.S. Department of Defense
- AAAmerican Association for the Advancement of Science
- SGSt. Giles FoundationAward: ANR-10-IAHU-01
- YUYale University
- GMGeorge Mason University
- GCGeorgia Clinical and Translational Science AllianceAward: UL1 TR001866
- IDInstitut des maladies génétiques ImagineAward: ANR-10-IAHU-01
- AUAmsterdam University Medical Centers
- ECEuropean CommissionAwards: COVID-19, COVID19
- ANAgence Nationale de la RechercheAwards: 2017-, 10-LABX-62-IBEID, ANR-15-RHU-0004, ANRS-COV05, ANR-20-COVI-0064, ANR-10-LABX-69-01, 10-LABX-69-01, 10-IAHU-01, ANR-10-LABX-62-IBEID, ANR-10-IAHU-01, ANR-10, ANR-15-IDEX-04-LUE, ANR-10-LABX-62, 15-IDEX-04-LUE, RHU-0004
- INInstitut National de la Santé et de la Recherche MédicaleAwards: ANR-10-IAHU-01, ANR-10-LABX-62-IBEID
- UOUniversity of New South Wales
- ZZonMw
- FTFondazione Telethon
- FPFondation pour la Recherche MédicaleAwards: ANR-10-LABX-62-IBEID, ANR-10-IAHU-01, EQU201903007798, EA20170638020
- NONederlandse Organisatie voor Wetenschappelijk OnderzoekAward: 20005
- MDMinisterio de Ciencia e InnovaciónAward: RTC-2017-6471-1
- FBFondation Bettencourt Schueller
- RLRegione Lombardia
- NINational Institutes of HealthAwards: U24HG008956, UM1HG006504, ANR-10-IAHU-01, R01AI091707-10S1, P01AI138398-S1, COVID-19, R01AI091707, TR001866, UL1 TR001866, R01AI088364, 2U19AI111825
- USUniformed Services University of the Health SciencesAward: ANR-10-IAHU-01
- MCMercatus Center, George Mason University
- MRMedical Research CouncilAward: COVID-19
- NHNational Health and Medical Research Council
- IDInstituto de Salud Carlos IIIAwards: COV20_01333, COV20_01334
- AEAgencia Estatal de InvestigaciónAward: RTC-2017-6471-1
- NHNational Human Genome Research InstituteAwards: UM1HG006504, U24HG008956
- NINational Institute of Allergy and Infectious DiseasesAwards: COVID-19, R01AI091707, 2U19AI111825, UL1 TR001866, ANR-10-IAHU-01, R01AI088364
- NCNational Center for Advancing Translational SciencesAwards: TR001866, UL1 TR001866
- NDNHLBI Division of Intramural Research